Canaccord Genuity Group set a C$12.50 price objective on Cipher Pharmaceuticals (TSE:CPH – Free Report) (NASDAQ:CPHR) in a report published on Monday morning,BayStreet.CA reports. The brokerage currently has a hold rating on the stock.
Cipher Pharmaceuticals Price Performance
Shares of CPH opened at C$11.76 on Monday. Cipher Pharmaceuticals has a 52 week low of C$8.01 and a 52 week high of C$19.69. The company has a current ratio of 2.00, a quick ratio of 2.67 and a debt-to-equity ratio of 41.22. The firm has a market cap of C$211.13 million, a price-to-earnings ratio of 12.99 and a beta of 1.20. The stock has a 50 day moving average of C$12.41 and a 200-day moving average of C$14.02.
Insider Transactions at Cipher Pharmaceuticals
In other Cipher Pharmaceuticals news, Director Harold Morton Wolkin sold 3,500 shares of the business’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of C$13.49, for a total transaction of C$47,215.00. Insiders own 42.00% of the company’s stock.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company’s geographical segments include Canada and the United States.
See Also
- Five stocks we like better than Cipher Pharmaceuticals
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore
- Dividend Capture Strategy: What You Need to Know
- Are Tariffs Threatening Disney’s Comeback Story?
- Differences Between Momentum Investing and Long Term Investing
- Is Alphabet a Generational Buying Opportunity at These Levels?
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
